Higher vs. Lower Doses of Dexamethasone for COVID-19 and Severe Hypoxia

Scandinavian Critical Care Trials Group1,000 enrolled

Overview

We aim to assess the benefits and harms of higher (12 mg) vs lower doses (6 mg) of dexamethasone on patient-centered outcomes in patients with COVID-19 and severe hypoxia.

Background: Preliminary results from the Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial have reported a reduction in 28-day mortality with low-dose dexamethasone (6 mg) once daily versus no intervention in hospitalised patients with COVID-19; an effect that may have been more pronounced in patients with increasing hypoxia. Yet, higher doses of dexamethasone may be beneficial in patients with non-COVID-19 acute respiratory distress syndrome. At present, it is unclear what dose of dexamethasone is most beneficial in patients with COVID-19 and severe hypoxia, and clinical equipoise exists. Objective: We aim to assess the effects of higher (12 mg) vs lower doses (6 mg) of intravenous dexamethasone on the number of days alive without life-support in adult patients with COVID-19 and severe hypoxia. Design: International, parallel-group, centrally randomised, stratified, blinded, clinical trial. Population: Adult patients with documented COVID-19 receiving at least 10 L/min of oxygen independent of delivery system OR mechanical ventilation. Experimental intervention: Dexamethasone 12 mg once daily for up to 10 days in addition to standard care. Control intervention: Dexamethasone 6 mg once daily for up to 10 days in addition to standard care. Outcomes: The primary outcome is days alive without life support (i.e. mechanical ventilation, circulatory support, or renal replacement therapy) at day 28. Secondary outcomes are serious adverse reactions (i.e. anaphylactic reaction to hydrocortisone, new episode of septic shock, invasive fungal infection or clinically important gastrointestinal bleeding) at day 28; days alive without life support at day 90; days alive and out of hospital at day 90; all-cause mortality at day 28, 90 and 180; and health-related quality of life at day 180. Sample size: A total of 1000 participants will be randomised in order to detect a 15% relative reduction in 28-day mortality combined with a 10% reduction in time on life support among the survivors with a power of 85%.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

1,000

Conditions

Covid19 Hypoxia

Interventions

DexamethasoneDRUG

ATC code: H02AB02

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: All of the following must be fulfilled * Aged 18 years or above AND * Confirmed SARS-CoV-2 (COVID-19) requiring hospitalisation AND * Use of one of the following: * Invasive mechanical ventilation OR * Non-invasive ventilation or continuous use of continuous positive airway pressure (CPAP) for hypoxia OR * Oxygen supplementation with an oxygen flow of at least 10 L/min independent of delivery system Exclusion Criteria: We will exclude patients who fulfil any of the following criteria: * Use of systemic corticosteroids for other indications than COVID-19 in doses higher than 6 mg dexamethasone equivalents * Use of systemic corticosteroids for COVID-19 for 5 days consecutive days or more * Invasive fungal infection * Active tuberculosis * Fertile woman (\<60 years of age) with positive urine human gonadotropin (hCG) or plasma-hCG * Known hypersensitivity to dexamethasone * Previously randomised into the COVID STEROID 2 trial * Informed consent not obtainable

Locations (53)

Outcomes

Primary Outcomes

Days alive without life support at day 28

Days alive without life support (i.e. invasive mechanical ventilation, circulatory support or renal replacement therapy) from randomisation to day 28

Time frame: Day 28 after randomisation

Secondary Outcomes

Number of participants with one or more serious adverse reactions

Serious adverse reactions defined as new episodes of septic shock, invasive fungal infection, clinically important gastrointestinal bleeding or anaphylactic reaction

Time frame: Day 28 after randomisation

All-cause mortality at day 28

Death from all causes

Time frame: Day 28 after randomisation

All-cause mortality at day 90

Death from all causes

Time frame: Day 90 after randomisation

Days alive without life support at day 90

Days alive without life support (i.e. invasive mechanical ventilation, circulatory support or renal replacement therapy) from randomisation to day 90

Time frame: Day 90 after randomisation

Days alive and out of hospital at day 90

Number of days alive and out of hospital not limited to the index admission

Time frame: Day 90 after randomisation

All-cause mortality at day 180

Death from all causes

Time frame: Day 180 after randomisation

Health-related quality of life at day 180

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Dept. of Anaesthesia and Intensive Care, Aalborg University Hospital, Denmark.

Aalborg, Denmark

Dept. of Intensive care, Aarhus University Hospital

Aarhus, Denmark

Dept. of Intensive Care, Copenhagen University Hospital, Rigshospitalet

Copenhagen, Denmark

Dept. of Neuroanaesthesiology

Copenhagen, Denmark

Dept. of Thoracic Anaesthesiology, Copenhagen University Hospital, Rigshospitalet

Copenhagen, Denmark

Dept of Infectious diseases, Copenhagen University Hospital, Rigshospitalet

Copenhagen, Denmark

Dept. of Intensive Care, Gentofte Hospital

Hellerup, Denmark

Dept. of Anaesthesia and Intensive Care, Herlev Hospital

Herlev, Denmark

Dept. of Anaesthesia, Regional Hospital West Jutland, Herning

Herning, Denmark

Dept. of Intensive Care, Nordsjællands Hospital - Hillerød, Denmark.

Hillerød, Denmark

...and 43 more locations